Cardiogen

Also known as: AEDR, Ala-Glu-Asp-Arg, Cardiogen peptide, cardioregulatory tetrapeptide

2 notable studies

View Supplier Listings Take This Cardiogen Study With You

TLDR

Cardiogen is the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), studied primarily in preclinical models of cardiac-cell aging, gene regulation, apoptosis, and tissue protection, but robust independently replicated human evidence demonstrating treatment or prevention of cardiovascular disease is currently lacking.

 Research Supports Studied for associations with cardiomyocyte aging and cell proliferation
Investigated for effects on apoptosis and oxidative stress in cardiac cells
Examined for relevance to myocardial-injury hypotheses, not a clinically established use
 

 Observations Reported in Research Reported to influence expression of proliferation, differentiation, and apoptosis-related proteins in cardiac cells under aging conditions (2010s in-vitro study)
Investigated for effects on gene-expression pathways related to cardiac-cell aging in cultured cells (2010s in-vitro study)
No human clinical trial evidence establishing cardiovascular benefit has been identified
 

These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.

At a Glance

Classification: Synthetic tetrapeptide; short peptide bioregulator; experimental cardiac-associated peptide

Cardiogen is the synthetic four-amino-acid peptide Ala-Glu-Asp-Arg or AEDR. It belongs to the Khavinson short-peptide-bioregulator family and is associated primarily with cardiac tissue. Published research has investigated AEDR in relation to cardiomyocyte aging, cardiac-cell proliferation, apoptosis, oxidative stress, gene expression, myocardial injury, and cellular senescence. The central Aminodex distinction is: Cardiogen is a cardiac-associated experimental peptide—not an established treatment for heart disease. The strongest evidence is preclinical, and much of it comes from the same interconnected peptide-bioregulator research network.

What Is Cardiogen?

Cardiogen is a tetrapeptide: Ala-Glu-Asp-Arg (AEDR). It was developed within research investigating whether very short peptide sequences derived from tissue-associated peptide preparations could reproduce specific biological effects. Cardiogen became associated with the heart/myocardium. The underlying hypothesis is that AEDR can influence regulatory processes in cardiac cells, particularly under aging, oxidative stress, injury, and cellular dysfunction. As with Cortagen, Cartalax and Vesugen, there is no established classical Cardiogen receptor. Instead, the research program emphasizes regulation of gene expression and cellular differentiation.

What Are Researchers Studying?

Cardiac-cell aging

One of Cardiogen's central research themes is age-associated deterioration of cardiac cells. Experimental work has examined whether AEDR can influence: cell proliferation, apoptosis, oxidative damage, differentiation, and gene expression. These findings support investigation of AEDR as a regulator of cardiac-cell biology. They do not establish reversal of human cardiac aging.

Cardiomyocyte proliferation

Cardiac tissue has limited regenerative capacity after injury. Researchers in the peptide-bioregulator field have investigated whether Cardiogen can alter proliferative activity in cardiac cells. Reported experiments suggest AEDR can increase expression of proliferation-associated markers under some experimental conditions. This is interesting because loss of cardiomyocytes contributes to declining cardiac function. Increased proliferation markers do not equal regeneration of a damaged human heart.

Apoptosis

Programmed cell death is involved in many forms of cardiac injury. Cardiogen has been studied for effects on proteins and genes associated with apoptosis, including systems involving p53, caspases, and Bcl-family signaling. Experimental findings have been interpreted as potentially anti-apoptotic or cell-protective under particular conditions. The clinical relevance remains uncertain.

Oxidative stress

Oxidative stress contributes to ischemic injury, mitochondrial dysfunction, cardiomyocyte damage, and age-associated cardiac changes. Cardiogen has been investigated in models involving oxidative damage. Researchers have reported changes consistent with altered antioxidant/cellular-stress responses. This does not establish Cardiogen as a clinically effective antioxidant or cardioprotective therapy.

Myocardial injury

Cardiogen research includes experimental models of myocardial damage. The broader hypothesis is that peptide-mediated regulation of cell survival and differentiation might improve tissue responses following injury. This is one of the areas where vendor language often jumps too far: experimental cardioprotection does not mean treatment for myocardial infarction or heart failure. There is no robust clinical evidence establishing Cardiogen for either.

Gene regulation

Like several other Khavinson peptides, Cardiogen has been investigated as a regulator of gene expression. The proposed model involves very short peptides interacting with cellular regulatory machinery and modifying transcription of genes associated with tissue function. Some publications from this research program propose direct peptide-DNA interactions. Those hypotheses remain much less established than conventional receptor pharmacology.

How Does It Work?

There is no firmly established single molecular target. The proposed framework is: AEDR → cellular uptake → interaction with gene-regulatory/chromatin-associated processes → changes in expression of proliferation, differentiation and apoptosis-related genes → changes in cardiac-cell behavior. Possible downstream processes investigated include oxidative-stress responses, apoptosis, cellular proliferation, and differentiation. This is a proposed regulatory mechanism, not a settled receptor pathway.

What Does the Research Show?

Human research

Human therapeutic evidence is very limited and insufficient to establish efficacy. The Cardiogen literature includes discussion of clinical use within the broader peptide-bioregulator research tradition, but the readily accessible evidence does not provide the sort of large randomized trials, blinded placebo controls, independently replicated outcomes, or cardiovascular-event endpoints needed to establish a cardiovascular therapy. There is no good evidence that Cardiogen prevents heart attacks, heart-failure hospitalization, cardiovascular death, arrhythmias, or atherosclerotic events. Human efficacy: NOT ESTABLISHED.

Animal research

Most efficacy-oriented evidence is preclinical. Experimental systems have examined AEDR in relation to myocardial aging, cardiac injury, oxidative stress, and cellular survival. These experiments provide a rationale for further study. They do not establish human cardiovascular benefit.

In-vitro research

This is the strongest evidence category. Cardiac-derived cell cultures and organotypic systems have been used to investigate proliferation, apoptosis, gene expression, differentiation, and aging. These studies demonstrate biological activity under experimental conditions.

Notable Studies

Effect of Cardiogen on the Expression of Signaling Molecules in Cardiomyocytes During Aging

in-vitro

2010s

Researchers investigated how AEDR influenced expression of proteins involved in proliferation, differentiation and apoptosis in cardiac cells under aging-related conditions. The reported findings supported the hypothesis that Cardiogen can modify molecular pathways involved in cardiomyocyte aging.

Limitations: Preclinical experimental system. Changes in signaling proteins or gene expression do not demonstrate improved cardiac function or cardiovascular outcomes in humans.

Short Peptides Regulate Gene Expression and Cellular Aging in Cardiac Tissue

in-vitro

2010s

Short tissue-associated peptides including AEDR were investigated for effects on gene-expression pathways related to cardiac-cell function and aging. Results were interpreted as supporting a regulatory role for short peptides in age-associated cardiac cellular changes.

Limitations: Concentrated investigator network, preclinical endpoints and uncertain independent replication. The research does not establish clinical cardioprotection.

What We Still Don't Know

Human pharmacokinetics; human bioavailability; primary molecular target; whether Cardiogen reaches human myocardium at meaningful concentrations; whether proposed DNA interactions occur in living humans; whether it improves ejection fraction; whether it improves exercise capacity; whether it reduces cardiac fibrosis; whether it reduces arrhythmias; whether it improves heart-failure outcomes; whether it prevents myocardial infarction; whether it reduces cardiovascular mortality; long-term human safety; drug interactions; whether effects independently replicate; whether research-market Cardiogen corresponds to experimental AEDR material.

Related Compounds

Take the Cardiogen research with you.

Get the Aminodex Cardiogen Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.

One-time email. We do not add you to any mailing list.

Supplier Listings

A directory of relevant research suppliers for this compound is not yet available.